Anthrax vaccines

Annals of Saudi Medicine

Volumn 25, Issue 2, 2005, Pages 143-149

  Splino, Miroslav ^a   Patocka, Jiri ^a   Prymula, Roman ^a   Chlibek, Roman ^a  

^a DEPARTMENT OF TOXICOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIBIOTIC AGENT; BACTERIAL ANTIGEN; FIBRINOGEN; FORMALIN INACTIVATED ANTHRAX SPORE; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; PROTHROMBIN; SODIUM CHLORIDE; ST 1 VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; WATER;

ANTHRAX; ARTHRALGIA; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BIOLOGICAL WARFARE; BIRTH DEFECT; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SYNTHESIS; EDEMA; EPIDEMIC; ERYTHEMA; FATALITY; FATIGUE; FLU LIKE SYNDROME; HUMAN; HYPEREMIA; IMMUNITY; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE REACTION; LETHAL GENE; LUNG INFECTION; MASS IMMUNIZATION; MYALGIA; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REVIEW; RUSSIAN FEDERATION; SKIN INDURATION; SKIN INFECTION; VACCINATION; VACCINATION REACTION;

EID: 18744371626     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2005.143     Document Type: Review

References (40)

1. Merka V, Patocka J. Anthrax: an important agent of biological terrorism. Nederl Milit Geneesk T. 2002;55:142-145.
2. Prymula R, Splino M, Chlibek R, Beran J, Fusek J, Bajgar J. Biological and Chemical Terrorism. Prague: Grada Publishing; 2002. (In Czech)
3. Splino M, Patocka J. Prophylaxis against anthrax. Acta Medica. 2002;45:85-88.
4. Inglesby TV, Henderson DA, Bartlett JG et al. Anthrax as a biological weapon: medical and public health management. JAMA. 1999;281:1735-1745.
5. Friedlander AM. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr Clin Top Infect Dis. 2000;20:335-349.
6. Zilinskas RA. Iraq's biological weapons. The past as future? JAMA. 1997;278:418-424.
7. CDC. Surveillance for adverse events associated with anthrax vaccination - U.S. Department of Defence, 1998-2000. MMWR. 2000;49:341-345.
8. Brachman PS. Inhalation anthrax. Ann N Y Acad Sci. 1980;353:83-93.
9. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266:1202-1208.
10. Friedlander AM, Welkas SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167:1239-1243.
11. Sirard JC, Guidi-Rontani C, Fouet A, et al. Characterization of a plasmid region involved in Bacillus anthracis toxin production and pathogenesis. Int J Med Microbiol. 2000;290:313-316.
12. Lacy DB, Collier RJ. Structure and function of anthrax toxin. Curr Top Microbiol Immunol 2002;271:81-85.
13. Brossier F, Mock M. Toxins of Bacillus anthracis. Toxicon. 2001;39:1747-1755.
14. Bhatnagar R, Batra S. Anthrax toxin. Crit Rev Microbiol. 2001;27:167-200.
15. Mahlandt BG, Klein F, Lincoln RE et al. Immunologic studies of anthrax: IV. Evaluation of the immunogenicity of three components of anthrax toxin. J Immunol. 1966;96:727-733.
16. Wright GG, Green TW, Kanode RJ Jr. Studies on immunity in anthrax. V. Immunizing activity of alum-precipitated protective antigen. J Immunol. 1954;73:387-391.
17. Turnbull PCB, Broster MG, Carman JA, et al. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun. 1986;52:356-363.
18. Brachman PS, Gold H, Plotkin SA et al. Field evaluation of a human anthrax vaccine. Am J Public Health. 1962;52:632-645.
19. Sato PA, Reed RJ, Smith TC, Wang L. Monitoring anthrax vaccine safety in US military service members an active duty: surveillance of 1998 hospitalizations in temporal association with anthrax immunization. Vaccine. 2002;20:2369-2374.
20. Chlibek R. BW Threat Reduction - Medical Prophylaxis. Proceedings of the Workshop on Multinational Cooperation in Development of Mobile Biological and NBC Analytical Laboratories, Hradec Králové, Czech Republic, 2003.
21. Slyakhov EN, Rubinstein E. Human live anthrax vaccine in the former USSR. Vaccine. 1994; 12:727-729.
22. Ginsburg NN. Anthrax vaccine STI. Collected Works of the Red Army Institute of Epidemiology and Hygiene. 1946;1:5-90 (In Russian).
23. Alexandrov NI, Gelen NE, Garin NS, et al. Experience in massive aerogenic vaccination of humans against anthrax. Voen Med Zh. 1959;8: 27-32. (In Russian)
24. Brachman PS, Friedlander AM. Anthrax. In: Plotkin SA, Mortimer EA, eds. Vaccines. 2nd ed., PA: WB Saunders Company. 1994:729-793.
25. Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994;12:542-550.
26. http://www.promedmail.org ProMED mail website Anthrax Vaccine, safety and efficacy (2002).
27. Wasserman GM, Grabenstein JD, Pittman PR, Rubertone MV, Gibbs PP, Wang LZ, Golder LG. Analysis of adverse events after anthrax immunization in US Army medical personnel. J Occup Environ Med. 2003 Mar;45(3):222-233.
28. Iowa Persian Gulf Study Group. Self-reported illness and health status among Gulf War veterans: a population-based study. JAMA. 1997;277: 238-245.
29. Brossier F, Levy M, Mock M. Anthrax spores make an essential contribution to vaccine efficacy. Infect Immun. 2002;70:661-664.
30. Cuyck H. Brief report on the 4th Anthrax Conference, Annapolis, USA, June 2001.
31. CDC. Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Exposure Management and Antimicrobial Therapy, December 2000, MMWR. 2000;49:No RR15, 13-14,
32. CDC. October 2001, MMWR. 2001;50:909-919,
33. CDC. November 2002, MMWR., 51:No.45,1025.
34. Mourez M, Kane RS, Mogridge J, et al. Designing a polyvalent inhibitor of anthrax toxin. Nat Biotechnol. 2001;19:958-961.
35. Zwick MB, Shen J, Scott JK. Phage-displayed peptide libraries. Curr Opin Biotechnol. 1998; 9:427-435.
36. Seppa NN. New anthrax treatment works in rats. Science News. 2001;159:296.
37. http://www.cdc.gov/mmwr/preview/mmwrhtml/ACIP website Use of Anthrax Vaccine in the United States (2002).
38. Lange JL, Lesikar SE, Rubertone MV, Brundage JF. Comprehensive systematic surveillance for adverse effects of anthrax vaccine absorbed, US Armed Forces, 1998-2000. Vaccine 2003; 21:1620-1628.
39. Baillie L, Hebdon R, Flick-Smith H, Williamson D. Characterisation of the immune response to the UK human anthras vaccine. FEMS Immunol Med Microbiol. 2003;36:83-86.
40. Sever JL, Brenner AI, Gale AD, Lyle JM, Moulton LH, Ward BJ, West DJ. Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf. 2004;13:825-840.